Follow us for updates
© 2021 reportr.world
Read the Story →

How Does Sinovac Compare to Other COVID Vaccines?

Manila approved it for emergency use.
by Agence France Presse
Feb 23, 2021
Photo/s: Shutterstock
Shares

With several COVID-19 vaccines either being rolled out or under trial, here is a rundown of the various stages of their development.

On the market 

SINOVAC

The Chinese-developed vaccine uses a similar technique and is authorized for use in China, Chile, Brazil Turkey, and most recently, the Philippines.

Others such as Ukraine and Uruguay have pre-ordered doses. 

Its makers say it is 50%  effective against COVID-19 (and 80% effective against severe illness), but trial results have not yet been made public.

SINOPHARM

Two vaccines developed in China use the traditional technique of injecting the deactivated virus in order to trigger an immune response.

As well as the United Arab Emirates, Hungary, Cambodia, Peru, and Zimbabwe have all started administering the vaccine, which its makers say is 79% effective.

PFIZER/BIONTECH

The mRNA vaccine developed by US pharma giant Pfizer and German start-up BioNTech is already approved for use in the European Union, the United States, Canada, Britain and several other nations.

Continue reading below ↓

Clinical trials showed the vaccine, which delivers instructions to the body to help the immune system identify and destroy COVID-19 molecules, is more than 95 percent effective.

MODERNA

Another mRNA vaccine, with a 94.1-percent efficacy rate, has been approved for use in the EU, North America, Britain, and several other nations, including Israel and Singapore.

ASTRAZENECA/OXFORD

This viral vector vaccine is authorized for use in the EU, Britain, and other countries such as India.

It was shown to be 60% effective in trials, but a relative lack of safety and efficacy data among older participants has led several countries to recommend against administering the vaccine to those over 65.

Continue reading below ↓
Recommended Videos

SPUTNIK V

Russia's vaccine works in a similar way to the AstraZeneca/Oxford jab, but has a 91.6% efficacy according to trial results.

More than a dozen nations have authorized its use, including Belarus, Armenia, Iran, Algeria, Argentina, South Korea, and Venezuela.

Continue reading below ↓

Its makers have begun the process of asking for approval from the European Medicines Agency. Hungary is the sole EU member state that has started administering doses.

JOHNSON & JOHNSON

The US pharma giant has asked for emergency use authorization for its single-shot vaccine in the US and EU.

South Africa became the first country to begin administering the Johnson & Johnson vaccine after saying it would prioritize its procurement over the AstraZeneca jab. 

Trials showed it to be 66% effective against COVID-19 and up to 85% effective against serious forms of infection.

BHARAT BIOTECH

This inactivated virus vaccine is used currently in India.

CANSINO

A Chinese-made viral vector vaccine was authorized for use in Mexico last week, but has not yet been administered to the public.

Authorization pending

NOVAVAX

This American vaccine is under rolling review by the EMA, which has the ultimate say on EU medical authorizations.

It is based on "sub-unit" proteins that trigger an immune response without delivering the whole virus. 

Continue reading below ↓

Its makers say it is 89.3% effective. 

CUREVAC

The German vaccine entered EMA review last week. It uses similar technology to the Moderna and Pfizer/BioNTech jabs.

Still in development

The World Health Organization says there are currently 69 vaccines against the novel coronavirus in human trials. 

An additional 180 candidate vaccines are under development but have yet to begin testing on humans.

ALSO READ:

UN Urges Global COVID Vaccine Plan, Warns of Dangerous Inequity

Shot in the Arm: Why the COVAX Facility for Vaccines Matters

Latest Headlines
Read Next
Recent News
For the first time in 19 months.
The senator committed no violation, his spokesperson said.
Senate corruption probe keeps going.
The greed of big tech leaders is doing us enormous damage.
The contracts were 'grossly disadvantageous' to the government.
The news. So what? Subscribe to the newsletter that explains what the news means for you.
The email address you entered is invalid.
Thank you for signing up to On Three, reportr's weekly newsletter delivered to your mailbox three times a week. Only the latest, most useful and most insightful reads.
By signing up to reportr.world newsletter, you agree to our Terms of Service and Privacy Policy.